The FDA recently announced that is has found small amounts of a probable carcinogen in versions of Zantac and other forms of ranitidine. JOHANNESBURG - The sale of the popular heartburn drug Zantac and its generic ranitidine products have been suspended.
Traces of a known carcinogen have been found in some of the products in the US. The CVS Health Corp said the suspension is a cautionary move. READ: US approves drug for post-partum depression Authorities are reviewing if traces of a known carcinogen pose a health risk to patients. US retailers have moved to remove Zantac products from shelves. The South African Health Products Regulatory Authority has also raised safety concerns. It has advised patients to speak to their healthcare professional before stopping or switching to other medicines.